Vakharia PP, et al. - A research was undertaken to validate patient-reported global atopic dermatitis (AD) severity in adults. For assessing AD severity in the clinical and epidemiological setting, patient-reported AD severity appeared to be sufficiently valid.

Methods

• The clinicians employed questionnaires and evaluation by a dermatologist (n=265) to perform a prospective dermatology practice-based study.

Results

• Patient-reported global AD severity significantly correlated with oSCORAD (Spearman rho=0.56 and 0.49), SCORAD (0.64 and 0.56), EASI (0.56 and 0.50), BSA (0.52 and 0.45), NRS-itch (0.60 and 0.53), POEM (0.50 and 0.48), and DLQI (0.50 and 0.49) (P<0.0001 for all), at baseline and follow-up.
• Results supported the association of patient-reported moderate and severe AD vs. mild AD with significantly higher oSCORAD, SCORAD, EASI, BSA, NRS-itch, POEM and DLQI (P<0.0001 for all).
• This study found moderate concordance between patient-reported AD severity (mild, moderate and severe) and previously developed severity strata for oSCORAD (kappa=0.39), SCORAD (kappa=0.47), EASI (kappa=0.37), NRS-itch (kappa=0.49), POEM (kappa=0.37), and DLQI (kappa=0.40).
• Data reported significantly greater absolute reductions of oSCORAD (-23.4/-9.7/-1.8), SCORAD (-33.0/-13.2/-2.3), EASI (-17.1/-9.8/-3.2), BSA (-46%/-15%/-4%), NRS-itch (-5/-2/0), POEM (-5/-2/0), and DLQI (-8/-6/-1) in those who reported mild or moderate disease on follow-up than those who continued to report severe disease (Kruskal-Wallis, P≤0.0003 for all), among patients with severe disease at baseline.